Good news in terms of strategy validation.
Although I am surprised with the US sales figure number of only USD$25m for 12 months to Sept 2020.
When Acrux filed to FDA in Aug 2020, the addressable market was around USD139m! Perhaps, there have been some bad news in terms of side effects for the testosterone product since that date...I'm not sure.
Ann: Acrux Receives FDA Approval - Generic Testosterone Solution, page-2
-
- There are more pages in this discussion • 80 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ACR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.11M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 142200 | 5.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.1¢ | 17617 | 1 |
View Market Depth
| Last trade - 15.27pm 07/11/2024 (20 minute delay) ? |
| ACR (ASX) Chart |
Day chart unavailable